EB病毒潜伏膜蛋白2A转染树突状细胞诱导特异性CTL杀伤鼻咽癌的体外、体内研究
|
摘要
鼻咽癌(nasopharyngeal carcinoma，NPC)为上皮来源的恶性肿瘤，高发于东南亚及我国华南地区。鼻咽癌通常不亦采用手术切除，放、化疗虽然对其有效，然而对部分病例并不能完全杀灭、清除肿瘤细胞，尤其是转移病灶和循环血液中的肿瘤细胞更难清除，并且治疗产生的副作用可进一步损伤机体免疫系统功能，部分患者易复发和转移。籍此，寻求有效的免疫治疗方法是鼻咽癌治疗研究的热点问题。
研究证实，机体抗肿瘤效应主要以细胞毒性T细胞(cytotoxicity T lymphocyte，CTL)介导的细胞免疫为主，肿瘤抗原必须经过抗原递呈细胞(antigen presenting cell，APC)加工、处理，才能激发有效的抗肿瘤免疫反应。树突状细胞(dendritic cell，DC)是目前发现功能最强、唯一能激活初始型T细胞并诱导机体产生初次免疫应答的APC。越来越多的证据表明，应用各种形式的抗原修饰DC，可在体内外诱导出特异性CTL，激发出有效的抗肿瘤免疫效应。近期体外、动物及临床研究已显示出DC在肿瘤治疗中的巨大应用前景。
进行CTL为基础的治疗前提是需选择一合适的肿瘤靶抗原。研究已证实EB病毒(Epstein-Barr virus，EBV)与鼻咽癌关系密切，该病毒是比较明确的DNA肿瘤病毒，近年血清流行病学、肿瘤EB病
Nasopharyngeal carcinoma (NPC) is a malignant tumor derived from the epithelial cells and occurs mainly in the Southeast Asia and South of China. NPC is usually difficult to be removed by surgery. Although radiotherapeutic and chemotherapeutic methods are effective for NPC, they could not eliminate tumor cells completely, especially those in circulatory systems and metastatic focuses. The immunologic function of the patients could also be damaged by these conventional methods during treatment. Relapse and metastasis of tumor occur usually in some NPC cases. Therefore, it is critically important to develop an immuno-therapeutic method for NPC.
It has been demonstrated that the cellular immunity, especially cytotoxic T cells (CTL) response, plays an important role in the immune response against tumor. Antigen presentation is critical for the initiation of adoptive immune responses. Dendritic cells (DC) are known as the most powerful and the only antigen-presenting cells (APC), which are capable of activating naive T cells and initiating primary immune response. More and more studies prove that DC pulsed with various
研究证实，机体抗肿瘤效应主要以细胞毒性T细胞(cytotoxicity T lymphocyte，CTL)介导的细胞免疫为主，肿瘤抗原必须经过抗原递呈细胞(antigen presenting cell，APC)加工、处理，才能激发有效的抗肿瘤免疫反应。树突状细胞(dendritic cell，DC)是目前发现功能最强、唯一能激活初始型T细胞并诱导机体产生初次免疫应答的APC。越来越多的证据表明，应用各种形式的抗原修饰DC，可在体内外诱导出特异性CTL，激发出有效的抗肿瘤免疫效应。近期体外、动物及临床研究已显示出DC在肿瘤治疗中的巨大应用前景。
进行CTL为基础的治疗前提是需选择一合适的肿瘤靶抗原。研究已证实EB病毒(Epstein-Barr virus，EBV)与鼻咽癌关系密切，该病毒是比较明确的DNA肿瘤病毒，近年血清流行病学、肿瘤EB病
Nasopharyngeal carcinoma (NPC) is a malignant tumor derived from the epithelial cells and occurs mainly in the Southeast Asia and South of China. NPC is usually difficult to be removed by surgery. Although radiotherapeutic and chemotherapeutic methods are effective for NPC, they could not eliminate tumor cells completely, especially those in circulatory systems and metastatic focuses. The immunologic function of the patients could also be damaged by these conventional methods during treatment. Relapse and metastasis of tumor occur usually in some NPC cases. Therefore, it is critically important to develop an immuno-therapeutic method for NPC.
It has been demonstrated that the cellular immunity, especially cytotoxic T cells (CTL) response, plays an important role in the immune response against tumor. Antigen presentation is critical for the initiation of adoptive immune responses. Dendritic cells (DC) are known as the most powerful and the only antigen-presenting cells (APC), which are capable of activating naive T cells and initiating primary immune response. More and more studies prove that DC pulsed with various
引文
[1] 洪明晃，郭翔主编．鼻咽癌．第1版．北京：中国医药科技出版社，2003，12．
[2] 田永泉主编．耳鼻咽喉-头颈外科学．第6版．北京：人民卫生出版社，2004，8．
[3] Thorley-Lawson DA, Lawson T, Babcock GJ. A model for persistent infection with Epstein-Barr virus: The stealth virus of human B cells. Life Sci, 1999, 65(14): 1433-1453.
[4] Henderson A, Ripley S, Heller M, et al. Human chromosome association of Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth transformwd in vitro. Proc Natl Acad USA, 1983, 80: 1987-1991.
[5] Liebowitz D, Kieff E. Epstein-Barr virus in the human herpesviruses. Roizman B, Whitley RJ, Lopez C eds New York, Raven Press, 1993, 107.
[6] Baumforth KRN, Young LS, Flavell KJ, et al. Demystified... The Epstein-Barr virus and its association with human cancers. J Clin Pathol: Mol Pathol, 2000, 52(6): 307-322.
[7] 王冬，贾心善．EB病毒相关肿瘤研究的新进展．国外医学，生理、病理科学与临床分册，1999，19(5)：338-340．
[8] Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol, 2000, 53: 248-254.
[9] Khanna R, Denis J, Moss SR, et al. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev, 1999, 170: 49-64.
[10] Khanna R, Tellam J, Duraiswamy J, et al. Immunotherapeutic strategies for EBV-associated malignancies. TRENDS in Molecular Medicine, 2001, 7(6): 270-276.
[11] Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med, 1993, 177: 339-49.
[12] Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. Motation Research, 2000, 462: 395-405.
[13] 骆建民，李恩民，李德锐，等．EB病毒和鼻咽癌．汕头大学医学院学报，2000，13(3)：67-70．
[14] 黎明，曹亚．EB病毒编码的蛋白质在癌变过程中的作用．国外医学，微生物学分册，2001，24：14-16．
[15] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol: Mol Pathol, 2000, 53 (5): 248-254.
[16] Everett EV, David NL, Ralph W. Nasopharyngeal carcinoma. The Lancet, 1997, 350: 1087-1091. [17] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3): 723-729.
[17] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3):723-729.
[18]Nonkwelo C, Skinner J, Bell A, et al.Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J virol, 1996, 70: 623-627.
[19] Wilson JB, Bell JL. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic. EMBO J,1996,15: 3117-3126
[20] Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 1995, 375: 685-688.
[21]Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/ proteasome- dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA, 1997,94: 12616-12621.
[22]Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma: evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res, 1998, 58:310-314.
[23]Khanna R, Burrows SR, Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54: 19-48.
[24]Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T-lymphocyte control of EBV- associated malignancies. J Virol, 1996, 70: 5357-5362.
[25]Izumi KM. Identification of EBV transforming genes by recombinant EBV technology. Sem Cancer Biol, 2001,11: 407-414.
[26] Imai S, Nishikawa, Takada K, et al. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol, 1998, 72 (2) : 4371-4378.
[27]Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 1995, 80(3): 389-399.
[28] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[29]Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 2000, 79, 176-200.
[30]Cambier JC, Pleiman CM, Clark MR. Signal-transduction by B cell antigen receptor and its coreceptors. Annu Rev Immunol, 1994, 12: 457-486.
[31] Scholle F, Longnecker R, Raab-Traub N. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein2: a role for C-terminal src kinase. J Virol, 1999, 73:4767-4775.
[32]Fruehling S, Longnecker R. The immunopreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated singnal transduction. J Virol, 1997,235: 241-251.
[33] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Ban" virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82:1451-1456.
[34] Ikeda M, Ikeda A, Longan LC, et al. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology, 2000, 268: 178-191.
[35] Ikeda M, Ikeda A, Longnecker R. PY motif of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J Virol, 2001,75(12): 5711-5718.
[36] Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol, 1994, 124(1-2):1-6.
[37] Chemey BW, Bhatia K, Tosato G, et al. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA, 1994, 91(26): 12967-12971.
[38] Mesic JB, Fletcher GH, Geopfert H, et al. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys, 1981, 7: 447-453.
[39] Esteller More E, Qure M, Fabra JM, et al. An epidemiological and clinical study of nasopharyngeal carcinoma. An Otorrinolaringol Ibero Am, 1990, 17 (5): 473-494.
[40] 马骏，麦海强，莫浩元，等．鼻咽癌放射治疗失败原因分析．癌症，2000，19(11)：1016-1018．
[41] Wang CC. Improved local control of NPC after intracavitary brachytherapy boost. Am J Ehin 0ncol, 1991, 14 (1): 825-832.
[42] 张有望，刘泰富，付慈禧．高剂量率后装腔内放射治疗鼻咽癌．中国放射肿瘤学，1987，7：477．
[43] 管忠震．鼻咽癌化学治疗的概况．癌症，1989，8(2)：120-122．
[44] Decker DA, Drelichman A, A1-Sarraf M. Chemotherapy for nasopharyngeal carcinoma: a ten-year experience. Cancer, 1983, 52: 602-605.
[45] Kourainy K, Crissman C, Ensiey J, et al. Excellent response to cisplatin-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol, 1988, 11: 427-430.
[46] Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx : a review of the Princess Margaret Hospital experience. Cancer, 1991, 68: 2120-2124.
[47] 曹卡加，黄惠英，毛志达，等．放疗加化疗治疗中晚期鼻咽癌的临床评价．癌症，1997，16(6)：445-447．
[48] 罗美华，覃强，温俄罗，等．放疗加化疗治疗晚期鼻咽癌的临床研究．癌症，2001，20(4)：409-411．
[49] Anne WM, Lee FRCR, Poon YF, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and pattems of failure. Int J Radiat. Oncol. Biol. Phys. 1992, 23 (2): 261-270.
[50] 崔念基，赵充，胡永红，等．鼻咽癌复发的影响因素及再程放疗的效果．癌症，1992，11(5)：375-378．
[51] Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 1993, 120 (1-2): 115-118.
[52] 刘名光，邝国乾，张奕敬，等．新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察．癌症，2000，19(10)：912-915．
[53] 张学荣，舒雨雁，王绍丰，等．胎盘调节因子对鼻咽癌放疗病人免疫功能的影响．广西医科大学学报，1997，14(1)：25-27．
[54] 胡永红，夏云飞，罗伟，等．血卟啉衍生物配合放疗对鼻咽癌患者免疫功能的影响及3年疗效观察．中国肿瘤临床，2000，27(6)：466-467．
[55] 邱健行，陈宁，冯惠强，等．薏苡仁酯配合化学药物治疗晚期鼻咽癌的临床研究．华夏医学，2002，15(1)：5-7．
[56] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 1999, 7:10416-10425.
[57] 杨世成，李树浓，刘芳等．转染B7-1基因至鼻咽癌细胞株及其诱导的细胞免疫应答．免疫学杂志，1998，14(3)：172-175．
[58] 李官成，谢鹭，周国华等．用抗独特型疫苗主动免疫治疗鼻咽癌病人的临床研究．癌症，1999，18(4)：372-375．
[59] LI Guancheng, Xie Lu, Zhou guohua et al. A clinical trial of active immunotherapy with anti-idiotpic vaccine in nasopharyngeal carcinoma patients. Chinese Medical Journal. 2002.115 (4): 567-570.
[60] 崔运昌，汪美先，王伯潭，等．人鼻咽癌上皮样细胞系的单克隆抗体(简报)．第四军医大学学报，1984，5：209-211．
[61] 孙去病，郭敏，李小玲，等．鼻咽癌的单克隆抗体研究：杂交瘤细胞系的建立及初步鉴定．湖南医学院学报，1987，12(1)：1-3．
[62] 李官成，谢鹭，孙去病，等．鼻咽癌抗独特型单克隆抗体的主动免疫初探．中国肿瘤生物治疗杂志，1997，4(4)：27 3-277．
[63] 曾春林，孙安涛，杜娟，等．白细胞介素-Ⅱ和LAK细胞对放疗后鼻咽癌患者细胞免疫功能的影响，湖南医学，2000，17(2)：88-89．
[64] 梁振强，陆海杰，黎福祥，等．CD3 AK细胞配合放疗治疗鼻咽癌的初步观察．广西医学，1999，21(3)：37 3-375．
[65] 陶仲强，司勇锋，张政，等．鼻咽癌的局部免疫治疗．陕西肿瘤医学，2001，9(2)：93-94．
[66] 苏勇，张锦明，黄晓明，等．IL-2在鼻咽癌化疗、放疗中的免疫调节作用．实用癌症杂志，2000，15(5)：499-501．
[67] 梁平，苏贞栋，梁静英，等．放疗并局部注射IL-2治疗鼻咽癌颈淋巴结转移残存的临床评价．中国临床药理学和治疗学，2002，7(4)：347-348．
[68] 吴玮，周水淼，李兆基，等．肿瘤坏死因子抗人鼻咽癌细胞的活性．第二军医大学学报，1997，18(3)：266-268．
[69] 董伟达，周蓉珏，周水淼，等．新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究．中华耳鼻咽喉科杂志，1998，33(1)：38-41．
[70] Steinman RM, Cohn ZA. Identification of a novell cell type in peripheral lymphoid organs of mice. Ⅰ. Morphology, quantiaton, tissue distribution. J Exp Med, 1973;137:1142-1162.
[71] Girolomoni G, Ricciardi-Castagnoli. Dendritic cells hold promise for immunotherapy. Immunology Today, 1997, 18:102-104.
[72] Schuler G, Steinman M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med, 1997, 186: 1183-1187.
[73] Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001, 106: 259-262.
[74] 丁传林，姚堃．树突状细胞的发育、亚群及其对T细胞应答类型的调控．上海免疫学杂志，2002，22：347-349．
[75] 朱学军，曹雪涛，马施华，等．人骨髓、脐血CD34~+干细胞体外扩增的树突状细胞的表型及其T细胞刺激活性分析．中国肿瘤生物治疗杂志，1999，6：22-26．
[76] 王晓，裴雪涛，李梁，等．脐血CD34~+细胞和外周血单核细胞两种来源的树突状细胞的特性的比较研究．中华血液杂志，1999，20：583-585．
[77] 谢芳艺，姚垫，王胜军，等．人外周血单核细胞体外诱导树突状细胞及鉴定．南京医科大学学报，2001，21：111-114．
[78] 王月丹，谢玮，邱玉华，等．细胞因子诱导不同来源的贴壁细胞分化为树突状细胞的研究．上海免疫学杂志，2000，3：140-144．
[79] 钱一峰，厉永建．树突状细胞与T辅助细胞分化．国外医学免疫学分册，2001．24：147-150．
[80] Tarte K, Klein B. Dendritic cell-based-vaccine: a promising approach for cancer immunotherapy. Leukemia, 1999, 13 (5): 653-663.
[81] Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev, 1999, 13 (1) :51-64.
[82] Subbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicitis protective cell-meiated immunity. Nat Med, 2001, 7 (5): 625-629.
[83] Marten A, Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother, 2000, 23 (4): 464-472.
[84] Celluzzi CM, Mayordommo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 1996,183 (1):283-287.
[85] Robbins PF, EI-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med, 1996,183 (3): 1185-1192.
[86] Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines J Exp Med, 1996, 183(1): 87-97.
[87] Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med, 1998, 4 (3): 328-332.
[88] Murphy G; Tjoa B, Ragde H, et al. Phase Ⅰ clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, 29 (6):371-380.
[89] Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. [J]. Cancer Res, 2001, 61 (17): 6445-6450.
[90]Dematos P, Abdel-wahab Z, Vervaert C, et al. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol, 1998, 185 (1): 65-74.
[91] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med, 1997,186 (7):1177-1182.
[92] Wan Y, Bramson J, Carter R, et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther, 1997,8(11): 1355-1363.
[93]Rea D, Johnson ME, Havenga MJE, et al. Strategies for improved antigen delivery into dendritic cells. TRENDS in molecular Medicine, 2001, 7: 94.
[94] Jenne L, Schuler G, Steinkasserer A, etal. Viral vectors for dendritic cell-based immunotherapy. TRENDS in immunology, 2001, 22: 102-107.
[95] Zhong L, Piperno AG, C hoi Y, etal. Recomibinant adenovirus is an efficient and non-perturbing genetic vector for human dendertic cells. Eur J Immunol, 1999, 29: 964-972.
[96]Dietz AB and Vuk-parlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood, 1998, 91: 392-398.
[97] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly (L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[98]Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods, 2000, 241: 69-81.
[99]Drillien R, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000, 268: 471-481.
[100] Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA, 1997,94 (7): 3183-3188.
[101] Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T response. J Exp Med, 1997,185: 1605-1617.
[102]Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol, 1999, 162: 3063-3069.
[103]Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol, 1997,15: 405-431.
[104]Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[105] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNAI [J]. J Immunol, 2000, 165:7078.
[106] Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res, 2002, 62 (1): 171-178.
[107] 姚堃，谢芳艺，许继军，等．EB病毒潜伏期膜蛋白2A基因重组痘苗病毒转染DC及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[108] Steven PL, Rosemary JT, Wendy AT, et al. Lee SP, Tierney RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[109] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[110] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus-specific T cell memory with peptide loaded dendritic cells. J of Virol, 1999, 73: 334-342.
[111] Subklewe M, Chahroudi A, Schmaijohn A, et al. Induction of Epstein-Barr virus specific cytotoxic T lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or uv-inactivated recombinant EBNA-3A vaccinia virus. Blood, 1999, 94: 1372-1381.
[112] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[113] Su Z, Peluso MV, Raffegerst SH, et al. The generation of Lmp2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr viruspositive Hodgkin disease. Eur J Immunol, 2001,31: 947-958.
[114] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to Lmp2A antigen: a potential treatment strategy for Epsstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[115] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B:a new modality for vaccination. J Virol, 1999, 7: 10416-10425.
[1] Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in Nasopharyngeal Carcinoma(NPC): Evidence for efficient presentation of Epstein-Ban" virus cytotoxic T-cell epitopes by NPC cells. Cancer Res, 1998, 58: 310-314.
[2] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451-1456.
[3] Steven PL, Rosemary JT, Wendy AT, et al. Lee SP, Tiemey RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[4] 洪明晃，郭翔主编．鼻咽癌．第1版．北京：中国医药科技出版社，2003，12．
[5] 冯浩森 综述，黄宗海审校．肿瘤疫苗的研究现状与进展．中国肿瘤临床与康复，2000，8(6)：124-126．
[6] 常卫红 综述．肿瘤疫苗研究进展．中国实用外科杂志，2001，21(9)：566-568．
[7] Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds.Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[8] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNA1 [J]. J Immunol, 2000, 165:70-78.
[9] Nonkwelo C, Skinner J, BellA, et al.Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.J virol, 1996, 70: 623-627.
[10] Wilson JB, Bell JL. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic. EMBO J, 1996, 15: 3117-3126.
[11] Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 1995, 375: 685-688.
[12] Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigenl. Proc Natl Acad Sci USA, 1997, 94: 12616-12621.
[13] Khanna R, Burrows SR, Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54:19-48.
[14] Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T lymphocyte control of EBVassociated malignancies. J Virol, 1996, 70: 5357-5362.
[15] Murry RJ, Young LS, Calender A, et al. Different patterns Epstein-Barr virus gene expression and cytotoxic T cell recognition in B cell lines infected with transforming (B95.8) or nontransforming (P3hR2) virus strains. J Virol, 1988, 62(3) :894-901.
[16] Murray RJ, Brooks JM, Rickinson AB, et al. Cross- recognition of a mouse H-1 peptide complex by human HLA-restricted cytotoxic T cells. Eur J Immunol, 1990, 20 (3): 659-664.
[17] 杨成勇，蔡伟民，沈倍奋，等．鼻咽癌患者EB病毒潜伏膜蛋白(LMPlA)的特异性细胞免疫研究．病毒学报，1999，15(3)：193-198．
[18] 周玲，姚家伟，陈志坚，等．免疫斑点法检测特异性EBV潜伏膜蛋白2合成肽的细胞毒T淋巴细胞．中华实验和临床病毒学杂志，2000，14(4)：384-385．
[19] Dawson CW, Rickinson AB, Young LS, et al. Epstein-Barr virus latent membrane protein inhibts human epithelial cell differentiation. Nature, 1990, 344 (6268): 777-781.
[20] Fahraeus R, Rymo L, Rhim JS, et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature, 1990, 345 (6274): 447-449.
[21] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[22] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol: Mol Pathol, 2000, 53 (5): 248-254.
[23] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly (L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[24] Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulat.ory capacity. J Immunol Methods, 2000, 241:69-81.
[25] Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000, 268:471-481.
[26] Murray RJ, Kurilla MG; Brooks JM, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med, 1992, 176: 157-168.
[27] Lettenne ET, Winberg G, Yadav M, et al. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur I Cancer, 1995,31: 1875-1878.
[28] Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1 [J]. J Ep Metl, 2000, 191: 1649-1660.
[29] Bickham K, Munz C, Tsang ML, et al. EBNAl-specific CD_4~+T cells in healthy carriers of Epstein-Barr virus are primarily Thl in function [J]. J Clin Invest, 2001, 107(1): 121-130.
[30]Babcock GJ, Decker LL, Freeman RB, et al. Epstein-barr virus infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients [J]. J Exp Med, 1999, 190 (4): 567-576.
[31] Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol, 1992,66 (5): 2689-2697.
[32] Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol, 1992, 66 (5): 3257-3262.
[33]Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[34]Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[35] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[36] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001,93:706-713.
[1] Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 1997, 90: 3245-3287.
[2]Inaba K. Dendritic cells as antigen-presenting cells in vivo. Immunol Cell Biol, 1997, 75: 206-208.
[3] Mailliard RB, Dallal RM, Son Yi, et al. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen [J]. Immunol Invest, 2000,29 (2): 177-185.
[4] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 1991, 9: 271-296.
[5]Dubois B, Vanbervliet B, Fayette J, et al. Dendritic cells enhance growth and differentiation of CD40- activated B lymphocytes. J Exp Med, 1997, 185: 941-951.
[6]Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 1998, 392: 245-252.
[7] Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med, 1999,50:507-529.
[8] Hsu FJ, et al. Vaccination of patients with B-cell lmphoma using autologous antigen-pulsed dendrtic cells. Nat Med, 1996,2: 52-59.
[9]Strunk D, Egger C, Leitner G, et al. A skin homing molecule defines the Langerhans cell progenitor in human peripheral blood. J Exp Med, 1997, 185: 1131-1136.
[10]Karolina AP, Nicolas T, Francoise SC, et al. Dendritic cells as the terminal stage of monocytes differentiation. J Immunol, 1998,160: 4587-4595.
[11] Res P, Martinez CE, Cristina JA, et al. CD34~+CD38~(dim) cells in the human thymus can differentiate into T, Nature Killer, and dendritic cells but are distinct from pluripotent stem cells. Blood, 1996, 87: 5196-5206.
[12] Steinman RM, Cohn ZA. Identification of a novell cell type in peripheral lymphoid organs of mice.I. Morphology, quantiaton, tissue distribution. J Exp Med, 1973,137:1142-1162.
[13] Young JW, Szabolcs P, Moore MAS. Identification of dendritic cell colony-forming units among normal human CD34~+ Bone marrow progenitors of GM-CSF and TNF-a. J Exp Med, 1995, 182: 1111-1120.
[14]Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA, 1997, 94: 12551-12556.
[15] Burt RK, Link C, Traynor A. Adoptive immunotherapy after hematopoietic stem cell transplantation. Curr Opin Onco, 1998,10: 525- 532.
[16] Van Voorhis WC, Hair LS. Steinman RM, et al. Human dentritic cells. Enrichment and characteristation from peripheral blood. J Exp Med, 1982, 155: 1172-1187.
[17] Dallal RM, Lotze MT. The dendritic cells and human cancer vaccines. Current Opinion in immunology, 2000,12: 583-588.
[18] Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol, 2000, 18: 245-273.
[19] Romani N, Gnmer S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med, 1994, 180: 83-93.
[20] 王月丹，谢玮，邱玉华等．细胞因子诱导不同来源的贴壁细胞分化为树突状细胞的研究．上海免疫学杂志，2000，3：140-144．
[21] 朱学军，曹雪涛，于益芝等．人外周血树突状细胞的体外扩增及鉴定．中国肿瘤生物治疗杂志，1997，4：302-306．
[22] 王晓，裴雪涛，李梁，等．脐血CD34~+细胞和外周血单核细胞两种来源的树突状细胞的特性的比较研究．中华血液杂志，1999，20：583-585．
[23] 谢芳艺，姚堃，王胜军，等．人外周血单核细胞体外诱导树突状细胞及鉴定．南京医科大学学报，2001，21：111-114．
[24] Chapuis F, Rosenzwajg M, Yagello M, et al. Differentiation of human dentritic cells from monocytes in vitro. Eur J Immunol, 1997, 27: 431-441.
[25] Alters SE, Gadea JR, Holm B, et al. IL-13 can substitute for IL-4 in the generation of dentritic cells for the induction of cytotoxic T lymphocytes and gene therapy. J Immunother, 1999, 22: 229-236.
[26] Ferlazzo G, Klein J, Paliard X, et al. Dentritic cells generated from CD_34~+ Progenitor cells with fit3 ligand, c-kit ligand, GM-CSF, IL-4, TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dentritic cells. J Immunother, 2000, 23: 48-58.
[27] Rosenzwajg M, Camus S, Guigon M, et al. The influence of interleukin (IL)-4,IL-13 and Flt3 ligand on human dendritic cell differentiation from cord blood CD34~+ progenitor cells. Exp Hematol, 1998, 26: 63-72.
[28] Alzona MT, Smith SL, van Epps DE, et al. Blood, 1996, 88 (suppl 1): 109a.
[29] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 1994, 179: 1109-1118.
[30] Engering AJ, Cella M, Fluitsma DM, et al. Mannose receptor mediated antigen uptake and presentation in human Dentritic cells. Adv Exp Med Biol, 1997, 417:183-187.
[31] Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 1997, 15: 94-103.
[32] Nouri-Shirazi M, Banchereau J, Fay J, et al. Dendritic cell based tumor vaccines. Immunology Letters, 2000, 74: 5-10.
[33] Gunzer M, Janich S, Varga G, et al. Dendritic cells and tumor immunity. Seminars in Immunology, 2001, 13: 291-302.
[34] Rhea D, Johnson ME, Havenga MJE, et al. Strategies for improved antigen delivery into dendritic cells. TRENDS in molecular Medicine, 2001, 7: 91-94.
[35] 鲁严，张学光．不同形式的肿瘤抗原负载树突状细胞的比较．癌症，2000，19：724-726．
[36] Jenne L, Schuler G, Steinkasserer A, et al. Viral vectors for dendritic cell-based immunotherapy. TRENDS in immunology, 2001, 22: 102-107.
[37]Zhong L, Piperno AG, Choi Y, et al. Recombination adenovirus is an efficient and non-perturbing genetic vector for human demdritic cells. Eur J Immunol, 1999, 29: 964-972.
[38] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[39]Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000,268(2): 471-481.
[40]Szabolcs P, Gallardo HF, Ciocon D H, et al. Retrovirally transduced human dendritic cells expressed a normal phenotype and potent T cell stimulatory capacity. Blood, 1997, 90: 2160-2167.
[41]Rouard H, Leno A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods, 2000, 241: 69-81.
[42]Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J.Virol, 1999, 73: 334-342.
[43] Subklewe M, Paludan C, Tsang ML, et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand Tumor-reactive CD8~+ killer T cells. J Exp Med, 2001, 193: 405-411.
[44] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[45] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001,93: 706-713.
[46]Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol, 2000, 53: 248-254.
[1] Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science, 1997, 276: 1684-1687.
[2] Stenger S, Modlin RL. Cytotoxic T cell responses to intracellular pathogens. Curr Opin Immunol, 1998, 10: 471-477.
[3] Baumforth KRN, Young LS, Flavell KJ, et al. Demystified...The Epstein-Barr virus and its association with human cancers. J Clin Pathol: Mol pathol, 2000, 52 (6): 307-322.
[4] Khanna, R, Burrows SR, Moss DJ, et al. Immune regulation in Epstein-Barr virus associated diseases. Microbiol Rev, 1995, 59: 387-405.
[5] 王冬，贾心善．EB病毒相关肿瘤研究的新进展．国外医学，生理、病理科学与临床分册，1999，19(5)：338-405．
[6] Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies:a review. J Clin Pathol, 2000, 53: 248-254.
[7] Straahof KC, Bollard CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children [J]. Oncologist, 2003, 8 (1): 83-98.
[8] Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection[J]. Blood, 2002, 100 (12) :4059-4066.
[9] Rooney CM, Aguilar LK, Huls MH, et al. Adoptive immunotherapy of EBVassociated malignancies with EBV-specific cytotoxic T-cell lines [J]. Curr Top Microbiol Immunol, 2001, 258:221-229.
[10] 骆建民，李恩民，李德锐，等．EB病毒和鼻咽癌．汕头大学医学院学报， 2000，13(3)：67-70．
[11] 黎明，曹亚．EB病毒编码的蛋白质在癌变过程中的作用．国外医学，微生物学分册，2001，24：14-16．
[12] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol : Mol Pathol, 2000, 53 (5): 248-254.
[13] Everett EV, David NL, Ralph W. Nasopharyngeal carcinoma. The Lancet, 1997, 350: 1087-1091.
[14] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3):723-729.
[15] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[16] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451-1456.
[17] 姚堃，谢芳艺，许继军，等．EB病毒潜伏期膜蛋白2A基因重组痘苗病毒转染DC及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[18] Lee SP, Tiemey RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[19] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[20] Rickinson A, E Kieff. Epstein-Barr virus[A]. Fields Virology [M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[21] Fong L, Engleman EG. Dendritic cells in cancer immunotherapy [J]. Annu Rev Immunol, 2000, 18: 245-273.
[22] Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54:19-48.
[23] Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAPol and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T-lymphocyte control of EBVassociated malignancies. J Virol, 1996, 70: 5357-5362.
[24] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[25] Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res, 2002, 62 (1): 171-178.
[26] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[27] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[28] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 1999, 7: 10416-10425.
[29] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001.93: 706-713.
[30] 杜海军，周玲，左建民等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究[J]．肿瘤学杂志，2004，10(2)：92-94．
[31] Su Z, Peluso MV, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol, 2001, 31: 947-958.
[32] Savoldo,B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus native individuals. J Immnol, 2002, 168:909-918.
[33] Subklewe M, Paludan C, Tsang ML, et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand Tumor-reactive CD8+ killer T cells. J Exp Med, 2001, 193:405-411.
[34] Leen A, P Meij, Ⅰ Redchenko, et al. Differential immunogenicity of Epstein-Ban virus (EBV) latent cycle proteins for human CD_4~+ T helper 1 responses [J]. J Virol, 2001, 75 (18): 8649-8659.
[35] Zhong L, Pipemo AG, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol, 1999, 29: 964-972.
[1] Cheng SW, Ting AC, Lam LK, et al. Carotid Stenosis After Radiotherapy for Nasopharyngeal Carcinoma. Arch Otolaryngol Head Neck Surg, 2000, 126: 517-521.
[2] Lam HC, Abdullah VJ,, Wormald PJ, et al. Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base. Otolaryngology-Head and Neck Surgery, 2001, 125(5): 522-527.
[3] 中国抗癌协会。新编常见恶性肿瘤诊治规范-鼻咽癌分册[M]．北京：北京医科大学中国协和医科大学联合出版社，1999．
[4] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[5] Marten A, Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother, 2000, 23 (4):464-472.
[6] Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med, 1996, 183: 87-97.
[7] Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med, 1998, 4 (3): 328-332.
[8] Murphy G, Tjoa B, Ragde H, et al. Phase Ⅰ clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, 29 (6): 371-380.
[9] Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines [J]. Cancer Res, 2001, 61 (17): 6445-6450.
[10] Demators P, Abdel-wahab Z, Vervaert C, et al. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. Cell Immunol, 1998, 185: 65-74.
[11] Zhang Haiging, Yao Kaitai, Zhu Hecheng, et al. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma epithelial cell line. Int J Cancer, 1990, 46: 944-949.
[12] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[13] Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med, 1992, 176: 157-168.
[14] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[15] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[16] Bollard CM, Straathof KCM, Helen Huls M, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother, 2004, 27(4): 317-327.
[17] 姚堃，谢芳艺，许继军，等．EB病毒潜伏膜蛋白2A基因重组痘苗病毒转染Dc及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[18] 杜海军，周玲，左建民等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究[J]．肿瘤学杂志，2004，10(2)：92-94．
[19] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumorextracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med, 1997, 186:1177-1182.
[20] liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg, 1999, 90: 1115-1124.
[21] 雷晓，余佩武，石彦，等．树突状细胞肿瘤疫苗诱导抗胃癌作用的实验研究．中华胃肠外科杂志，2002，5(1)：45-48．
[22] 刘福生，王忠诚，历俊华，等．肿瘤抗原致敏树突状细胞瘤苗治疗颅内胶质瘤的实验研究．中华神经外科杂志，2002，18(2)：91-95．
[1] Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients [J]. Proc Natl Acad sci USA, 1987, 84(9):2911-2915.
[2] Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine,1998,4(3):321-327
[3]Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol, 1996,157: 2539-2548.
[4] Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response [J]. J Immunother,1999,22 (4): 288-298.
[5]Zaremba S, Brazaga E, Zhu MZ, et al. Identification of an enhancer agonist cytotoxic T ymphocyte peptide from human carcinoembryonic antigen Cancer Res, 1997, 57: 4570-4577.
[6] Esserman LJ, Lopez T, Montes R, et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice [J]. Cancer Immunol Immunother, 1999,47 (6):337-342.
[7]Ohnishi Y, Fujii H,Murakani K, et al. A new pseudo-peptide analogue of the Arg-Gly-Asp (RGD) sequence inhibits liver metastasis of colon 26-L5 carcinoma cells. [J]. Cancer Letters, 1998,124: 157-163.
[8] Bonfanti M, Tavema S, Salmona m, et al. p21 WAF1 -derived peptides linked to an internalization peptide inhibit human cancer cell growth. [J]. Cancer Research, 1997, 57: 1442-1446.
[9] Tuteja R. DNA vaccines: a ray of hope [J]. Crit Rev Biochem Mol Biol, 1999, 34 (1): 1-24.
[10] Han R, et al. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Viral, 2000, 74 (20): 9712-9716.
[11] Bohm W, et al. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection Cancer Immunol Immunother,1997,44(4):230-238.
[12] White SA, et al. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine J Gene Med,2000,2(2):135-140.
[13]Xiang R,Silletti S, Lode HN, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice [J].Clin Cancer Res, 2001,7 (3 Suppl): 856s-864s.
[14] Geissler M, Wands G, Gesien A, et al. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. [J]. Lab Invest, 1997,76 (6): 859-871.
[15] Park JH, et al. Effective immunotherapy of cancer by DNA vaccination. Mol Cells,1999,9(4): 384-391.
[16] Nawrath M, Pavlovic J, Dummet R, et al. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17.[J]. Leukemia, 1999,13 (Suppl 1): S48-51.
[17]Petersen TR, et al. Human p53 (264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett, 1999,137(2): 183-191.
[18] Chen Y , Hu D, Eling DJ, et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.[J]. Cancer Res,1998, 58 (9): 1965-1971.
[19]Amici A, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice Gene Ther, 2000,7 (8): 703-706.
[20]Rakhmilevich AL, Janssen K,Turner J, et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12.[J]. Hum Gene Ther, 1997, 8 (11): 1303-1311.
[21]Mendiratta SK, Thai G, Eslaki NR, et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. [J]. Cancer Res, 2001, 61 (3): 859-862.
[22]Yoshimura K, et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther, 2001, 8 (1): 9-16.
[23] Irvine KR, Rao JB, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases [J]. J Immunol, 1996, 156 (1): 238-245.
[24] Chamberlain RS. Prospects for the therapeutic use of anticancer vaccines.[J]. Drugs, 1999, 57(3): 309-325.
[25]Hui K,Grosveld F, Festenstein H, et al. Rejective of transplantable AKP leukaemia cells following MHC DNA-mediated cell transformation [J]. Nature , 1984, 311 (6010): 750
[26] James RF, Edwards S, Hui RM, et al. The effect of class 2 gene transfection on the tumorigenicity of the H-2k-negative mouse leukaemia cell line K36.16. [J]. Immunology, 1991, 72(2): 213-218.
[27] Schwann RN. Costimulation of T lymphocytes: the role of CD28,CTL-4 and B7/ BB1 in IL-2 production and immunotherapy [J]. Cell, 992,71 (7): 1065-1068.
[28]Fenton RT, Bate SE, Sonnevel T, et al. A phase I trial of B7-transfected or parental lethally irradiated allogenetic melanoma cell lines to induce cell- mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage Ⅳ melanoma[J]. Human Gene Therapy, 1995; 6 (1): 87
[29] Thomas MC, Greten TF, Pardoll DM, et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther, 1998, 9 (6): 835-843.
[30]Manome Y, Wen PY, Hershowitz A, et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother, 1995,41 (4): 227-235.
[31]Thara H, Sandgren EP, Quaife CJ, et al. Antitumor effects of IL-12: application for the immunotherapy and gene therapy of cancer [J]. Ther Gene, 1995, 2 (2): 96
[32] Miller AR, Reters WT, Posner M, et al. Cytokine mediated gene therapy for cancer [J]. Am Surg Oncol, 1994, 1 (5): 436
[33]Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry [J]. J Clin Oncol, 1998,16: 2548-2556.
[34]Cebon JS, Cieschke GJ. Granulocyte-macrophage colony-stimulating factor for cancer treatment [J]. Oncology, 1994, 51(2): 177-188.
[35] Garcia VE, Jullien D,Song M, et al. IL-15 enhaunces the response of human gamma delta T cells to nonpeptide microbial antigens [J]. J Immunol, 1998, (Correctiom of non petide) 160 (9): 4322-4329.
[36] Osaki T, Peron JM, Cai Q, et al. INF-gamma-induced factor/IL-18 administration mediates INF-gamma and IL-12-independent antitumor effects[J]. Jimmunol, 1998,160(4): 1742-1749.
[37] Mullen CA, Petropoulos D, Lowe RM, et al. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res, 1996, 56(6): 1361-1366.
[38] Witting B, Marten A, Dorbic T, et al. Therapeutic vaccination anginst metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I /II trial. Hum Gene Ther, 2001,12 (3): 267
[39] Antonia SJ, Seigne JD. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol, 2000,18 (2): 157
[40]Tarte K, Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia, 1999,13 (5): 653
[41]Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev, 1999,13 (1): 51
[42]Subbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicitis protective cell-meiated immunity. Nat Med, 2001,7(5): 625
[43] Marten A,Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother , 2000, 23 (4): 464-472.
[44] Celluzzi CM, Mayordommo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 1996,18 (1) : 283-287.
[45]Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med, 1996,183(3): 1185-1192.
[46]Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 1996; 183 (1): 87-97.
[47] Nestle FO, Alijagic S, Gilliet M,et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998,4 (3): 328-332.
[48] Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996,29 (6): 371-380.
[49]Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines [J]. Cancer Res, 2001, 61(17): 6445-6450.
[50]Dematos P, Abdel-wahab Z, Vervaert C, et al. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol, 1998, 185 (1): 65-74.
[51] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med,1997,186 (7): 1177-1182.
[52] Wan Y, Bramson J, Carter R, et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.. Hum Gene Ther, 1997, 8 (11): 1355-1363.
[53] Gong J, Avigan D, Chen D, et al. activation of antitumor cytotoxic T lymphocytes by fushions human dendritic cells and breast carcinoma cells. [J]. Proc Natl Acad Sci USA, 2000, 97 (6): 2715-2718.
[54] Gong J, Nikrui N, Chen D, et al. Fushions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. [J]. J Immunol, 2000, 165 (3): 1705-1711.
[55]Kugler A, Stuhler G, Walden P. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med, 2000, 6 (3): 332
[56] Hsu FJ,Benike C,Fagnoni F,et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 1996,2 (1): 52-58.
[57] Okada N, Tsujino M, Hagiwara Y, et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.[J]. Br J Cancer, 2001, 84(11): 1564-1570.
[58] Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.[J]. Cancer Res, 2001, 61 (2): 641-646.
[59] Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA, 1997,94 (7): 3183-3188.
[60] Mulders P, Pang S, Dannull J, et al. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates Cancer Res ,1998;58(5):956-961.
[61]Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage iVmelanoma[J]. Proc Natl Acad sci USA, 1992, 89 (2): 466-470.
[62] Durrant LG, Maxwell-Armstrong C, Buckley D, et al. A neoadjuvant clinical trial in colorental cancer patients of the human anti-idiotypic antibody 105 AD7, which mimics CD55. Clin Cancer Res, 2000,6 (2): 422
[63] Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. [J]. J Clin Oncol, 1999, 17(9): 2889-2895.
[64] Hamilton JM, Chen AP, Nguyen B, et al. Phase I study of recombinant vaccinia virus that expresses human carcinoembryonic antigen in adult patients with adenocarcinoma [J]. Proc Am Soc Clin Oncol, 1994, 13:295
[65] Schlag P, Manasterski M, Gerneth Thomas, et al. Active specific immuno-therapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evalution of clinical response of a phase Ⅱ trial[J]. Cancer Immunother, 1992, 35 (5):325-330.
[66] Gou YJ, Wu MC, Chen H, et al. Effective tumor vaccine generated by fusion of hepatoma cells with actived B cells[J]. Sci, 1994, 263:518-520.
[67] 冯浩森 综述，黄宗海审校．肿瘤疫苗的研究现状与进展．中国肿瘤临床与康复，2000，8(6)：124
[67] 常卫红 综述．肿瘤疫苗研究进展．中国实用外科杂志，2001，21(9)：566
[68] 刘衫杉 综述．叶胜龙审校．国外医学肿瘤学分册，1999，26(3)：131
[69] 王鹏飞 综述．肿瘤疫苗的研究进展．国外医学免疫学分册，2002，25(4)：220
[70] 温斌 综述．DNA疫苗与抗肿瘤免疫．国外医学免疫学分册，2003，26(1)：17
[1] Mesic JB, Fletcher GH, Geopfert H, et al. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys, 1981, 7: 447-453.
[2] Cheng SW, Ting AC, Lam LK, et al. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg, 2000; 126 (4) :517-521.
[3] Lam HC, Abdullah VJ, Wormald PJ, et al. Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base. Otolaryngology - Head and Neck Surgery, 2001;125 (5) : 522-527.
[4] Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 1993, 120 (1-2): 115-118.
[5] Townsend SE, Allison JP. Tumor rejection after direct costimulation of CDS+ T cells by B7-transfected melanoma cells, Science, 1993; 259(5093): 368-370
[6] 杨世成，李树浓，刘芳等．转染B7-1基因至鼻咽癌细胞株及其诱导的细胞免疫应答．免疫学杂志，1998；14(3)：172-175
[7] Nisonoff A, Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin Immunopathol, 1981; 21 (3): 397-406
[8] Li GC, Xie L, Zhou GH, et al. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients. Chinese Medical Journal, 2002; 115(4): 567-570
[9] 谢鹭，李官成，孙去病，等．用抗独特型抗体主动免疫增强鼻咽癌放疗病人的免疫功能．中国肿瘤临床，1998；25(3)：168-171
[10] Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[11] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNA1 [J]. J Immunol, 2000, 165:7078.
[12] Subklewe M, Chahroudi A, Schmaijohn A, et al. Induction of Epstein-Barr virus specific cytotoxic T lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or uv-inactivated recombinant EBNA-3A vaccinia virus. Blood, 1999, 94: 1372-1381.
[13] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[14] Su Z, Peluso MV, Raffegerst SH, et al. The generation of Lmp2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol, 2001,31: 947-958.
[15] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to Lmp2A antigen: a potential treatment strategy for Epsstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[16] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B:a new modality for vaccination. J Virol, 1999, 7:10416-10425.
[17] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82:1451-1456.
[18] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[19] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[20] 徐洁洁，姚堃，俞晨杰，等．EB病毒LMP2A在鼻咽癌患者肿瘤组织中的表达及意义．临床耳鼻咽喉科杂志，2005，19(11)：484-487．
[21] 杜海军，周玲，左建民，等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究．肿瘤学杂志，2004，10(2)：92-94．
[22] 徐洁洁，姚堃，俞晨杰，等．EB病毒潜伏膜蛋白2A诱导细胞毒性T细胞抗鼻咽癌的体内外实验．中华耳鼻咽喉头颈外科杂志，2006，41(1)：54-59．
[23] 曾春林，孙安涛，杜娟，等．白细胞介素-Ⅱ和L A K细胞对放疗后鼻咽癌患者细胞免疫功能的影响，2000；17(2)：88-89．
[24] 梁振强，陆海杰，黎福祥，等．CD3 AK细胞配合放疗治疗鼻咽癌的初步观察．广西医学．1999；21(3)：37 3-375．
[25] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus-specific T cell memory with peptide loaded dendritic cells. J of Virol, 1999, 73: 334-342.
[26] 崔运昌，汪美先，王伯潭，等．人鼻咽癌上皮样细胞系的单克隆抗体(简报)．第四军医大学学报，1984，5：209-211．
[27] 孙去病，郭敏，李小玲，等．鼻咽癌的单克隆抗体研究：杂交瘤细胞系的建立及初步鉴定．湖南医学院学报，1987，12(1)：1-3．
[28] 李官成，朱建高，周国华，等．体内体外联合免疫法制备抗鼻咽癌单克隆抗体．湖南医学，1999；16(5)：326-328．
[29] Green WC, Leonard WJ, Deppen TM, et al. The human inter-leukin 2 receptor: normal and abnormal express in T cell and in leukemia induced by the human T-lymphotropism retroviruses[J]. Ann Inem Med, 1986,105:560-572.
[30] 陶仲强，司勇锋，张政，等．鼻咽癌的局部免疫治疗．陕西肿瘤医学，2001，9(2)：93-94．
[31] 苏勇，张锦明，黄晓明，等．IL-2在鼻咽癌化疗、放疗中的免疫调节作用．实用癌症杂志，2000，15(5)：499-501．
[32] 梁平，苏贞栋，梁静英，等．放疗并局部注射IL-2治疗鼻咽癌颈淋巴结转移残存的临床评价．中国临床药理学和治疗学，2002，7(4)：347-348．
[33] 吴玮，周水淼，李兆基，等．肿瘤坏死因子抗人鼻咽癌细胞的活性．第二军医大学学报，1997，18(3)：266-268．
[34] 董伟达，周蓉珏，周水淼，等．新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究．中华耳鼻咽喉科杂志，1998，33(1)：38-41．
[35] 张康，吴伟健．鼻咽癌患者放疗前外周T细胞及其亚群的检测与临床分期的关系．癌症，1995：14(5)：380-381．
[36] 张学荣，舒雨雁，王绍丰，等．胎盘免疫调节因子对鼻咽癌放疗病人免疫功能的影响．广西医科大学学报，1997；14(1)：25-27．
[37] 胡永红，夏云飞，罗伟，等．血卟啉衍生物配合放疗对鼻咽癌患者免疫功能的影响及3年疗效观察．中国肿瘤临床，2000；27(6)：466-467．
[38] 邱健行，陈宁，冯惠强，等．薏苡仁酯配合化学药物治疗晚期鼻咽癌的临床研究．华夏医学，2002；15(1)：5-7．
[39] 李坚，陆永奎．参麦注射液对鼻咽癌放疗病人免疫功能的影响．中国中医急症，1998；7(3)：118-119．
[40] 谢方云，曾智帆，黄惠英，等．放疗联合人参多糖注射液治疗鼻咽癌的临床观察．中国中西医结合杂志，2001；21(5．)：332-334．
[41] 穆美云，田洁，郜岚，等。黄芪对EB病毒核壳抗原IgA抗体阳性的作用。中华耳鼻咽喉科杂志，1993，28(1)：38-40．
[42] Csatary L, Gergely P. Vaccine therapy of malignant tumors[J]. Orv Hetil, 1990, 131 (47): 2585-2588.
[43] 李杰恩，徐志丈，毛荣清，等．新城疫病毒疫苗对晚期鼻咽癌患者细胞免疫功能的影响．细胞与分子免疫学杂志，2001，17(2)：155-156．
[44] 刘名光，邝国乾，张奕敬，等．新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察．癌症，2000；19(10)：912-915．
[44] 邝国乾，谢成熹，黄光武，等．新城疫病毒疫苗对自然人群EB病毒VCA-IgA抗体转阴作用初步报告．广西医科大学学报，1998，15(4)：4-6．
[2] 田永泉主编．耳鼻咽喉-头颈外科学．第6版．北京：人民卫生出版社，2004，8．
[3] Thorley-Lawson DA, Lawson T, Babcock GJ. A model for persistent infection with Epstein-Barr virus: The stealth virus of human B cells. Life Sci, 1999, 65(14): 1433-1453.
[4] Henderson A, Ripley S, Heller M, et al. Human chromosome association of Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth transformwd in vitro. Proc Natl Acad USA, 1983, 80: 1987-1991.
[5] Liebowitz D, Kieff E. Epstein-Barr virus in the human herpesviruses. Roizman B, Whitley RJ, Lopez C eds New York, Raven Press, 1993, 107.
[6] Baumforth KRN, Young LS, Flavell KJ, et al. Demystified... The Epstein-Barr virus and its association with human cancers. J Clin Pathol: Mol Pathol, 2000, 52(6): 307-322.
[7] 王冬，贾心善．EB病毒相关肿瘤研究的新进展．国外医学，生理、病理科学与临床分册，1999，19(5)：338-340．
[8] Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol, 2000, 53: 248-254.
[9] Khanna R, Denis J, Moss SR, et al. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev, 1999, 170: 49-64.
[10] Khanna R, Tellam J, Duraiswamy J, et al. Immunotherapeutic strategies for EBV-associated malignancies. TRENDS in Molecular Medicine, 2001, 7(6): 270-276.
[11] Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med, 1993, 177: 339-49.
[12] Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. Motation Research, 2000, 462: 395-405.
[13] 骆建民，李恩民，李德锐，等．EB病毒和鼻咽癌．汕头大学医学院学报，2000，13(3)：67-70．
[14] 黎明，曹亚．EB病毒编码的蛋白质在癌变过程中的作用．国外医学，微生物学分册，2001，24：14-16．
[15] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol: Mol Pathol, 2000, 53 (5): 248-254.
[16] Everett EV, David NL, Ralph W. Nasopharyngeal carcinoma. The Lancet, 1997, 350: 1087-1091. [17] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3): 723-729.
[17] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3):723-729.
[18]Nonkwelo C, Skinner J, Bell A, et al.Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J virol, 1996, 70: 623-627.
[19] Wilson JB, Bell JL. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic. EMBO J,1996,15: 3117-3126
[20] Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 1995, 375: 685-688.
[21]Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/ proteasome- dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA, 1997,94: 12616-12621.
[22]Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma: evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res, 1998, 58:310-314.
[23]Khanna R, Burrows SR, Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54: 19-48.
[24]Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T-lymphocyte control of EBV- associated malignancies. J Virol, 1996, 70: 5357-5362.
[25]Izumi KM. Identification of EBV transforming genes by recombinant EBV technology. Sem Cancer Biol, 2001,11: 407-414.
[26] Imai S, Nishikawa, Takada K, et al. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol, 1998, 72 (2) : 4371-4378.
[27]Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 1995, 80(3): 389-399.
[28] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[29]Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 2000, 79, 176-200.
[30]Cambier JC, Pleiman CM, Clark MR. Signal-transduction by B cell antigen receptor and its coreceptors. Annu Rev Immunol, 1994, 12: 457-486.
[31] Scholle F, Longnecker R, Raab-Traub N. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein2: a role for C-terminal src kinase. J Virol, 1999, 73:4767-4775.
[32]Fruehling S, Longnecker R. The immunopreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated singnal transduction. J Virol, 1997,235: 241-251.
[33] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Ban" virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82:1451-1456.
[34] Ikeda M, Ikeda A, Longan LC, et al. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology, 2000, 268: 178-191.
[35] Ikeda M, Ikeda A, Longnecker R. PY motif of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J Virol, 2001,75(12): 5711-5718.
[36] Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol, 1994, 124(1-2):1-6.
[37] Chemey BW, Bhatia K, Tosato G, et al. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA, 1994, 91(26): 12967-12971.
[38] Mesic JB, Fletcher GH, Geopfert H, et al. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys, 1981, 7: 447-453.
[39] Esteller More E, Qure M, Fabra JM, et al. An epidemiological and clinical study of nasopharyngeal carcinoma. An Otorrinolaringol Ibero Am, 1990, 17 (5): 473-494.
[40] 马骏，麦海强，莫浩元，等．鼻咽癌放射治疗失败原因分析．癌症，2000，19(11)：1016-1018．
[41] Wang CC. Improved local control of NPC after intracavitary brachytherapy boost. Am J Ehin 0ncol, 1991, 14 (1): 825-832.
[42] 张有望，刘泰富，付慈禧．高剂量率后装腔内放射治疗鼻咽癌．中国放射肿瘤学，1987，7：477．
[43] 管忠震．鼻咽癌化学治疗的概况．癌症，1989，8(2)：120-122．
[44] Decker DA, Drelichman A, A1-Sarraf M. Chemotherapy for nasopharyngeal carcinoma: a ten-year experience. Cancer, 1983, 52: 602-605.
[45] Kourainy K, Crissman C, Ensiey J, et al. Excellent response to cisplatin-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol, 1988, 11: 427-430.
[46] Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx : a review of the Princess Margaret Hospital experience. Cancer, 1991, 68: 2120-2124.
[47] 曹卡加，黄惠英，毛志达，等．放疗加化疗治疗中晚期鼻咽癌的临床评价．癌症，1997，16(6)：445-447．
[48] 罗美华，覃强，温俄罗，等．放疗加化疗治疗晚期鼻咽癌的临床研究．癌症，2001，20(4)：409-411．
[49] Anne WM, Lee FRCR, Poon YF, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and pattems of failure. Int J Radiat. Oncol. Biol. Phys. 1992, 23 (2): 261-270.
[50] 崔念基，赵充，胡永红，等．鼻咽癌复发的影响因素及再程放疗的效果．癌症，1992，11(5)：375-378．
[51] Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 1993, 120 (1-2): 115-118.
[52] 刘名光，邝国乾，张奕敬，等．新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察．癌症，2000，19(10)：912-915．
[53] 张学荣，舒雨雁，王绍丰，等．胎盘调节因子对鼻咽癌放疗病人免疫功能的影响．广西医科大学学报，1997，14(1)：25-27．
[54] 胡永红，夏云飞，罗伟，等．血卟啉衍生物配合放疗对鼻咽癌患者免疫功能的影响及3年疗效观察．中国肿瘤临床，2000，27(6)：466-467．
[55] 邱健行，陈宁，冯惠强，等．薏苡仁酯配合化学药物治疗晚期鼻咽癌的临床研究．华夏医学，2002，15(1)：5-7．
[56] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 1999, 7:10416-10425.
[57] 杨世成，李树浓，刘芳等．转染B7-1基因至鼻咽癌细胞株及其诱导的细胞免疫应答．免疫学杂志，1998，14(3)：172-175．
[58] 李官成，谢鹭，周国华等．用抗独特型疫苗主动免疫治疗鼻咽癌病人的临床研究．癌症，1999，18(4)：372-375．
[59] LI Guancheng, Xie Lu, Zhou guohua et al. A clinical trial of active immunotherapy with anti-idiotpic vaccine in nasopharyngeal carcinoma patients. Chinese Medical Journal. 2002.115 (4): 567-570.
[60] 崔运昌，汪美先，王伯潭，等．人鼻咽癌上皮样细胞系的单克隆抗体(简报)．第四军医大学学报，1984，5：209-211．
[61] 孙去病，郭敏，李小玲，等．鼻咽癌的单克隆抗体研究：杂交瘤细胞系的建立及初步鉴定．湖南医学院学报，1987，12(1)：1-3．
[62] 李官成，谢鹭，孙去病，等．鼻咽癌抗独特型单克隆抗体的主动免疫初探．中国肿瘤生物治疗杂志，1997，4(4)：27 3-277．
[63] 曾春林，孙安涛，杜娟，等．白细胞介素-Ⅱ和LAK细胞对放疗后鼻咽癌患者细胞免疫功能的影响，湖南医学，2000，17(2)：88-89．
[64] 梁振强，陆海杰，黎福祥，等．CD3 AK细胞配合放疗治疗鼻咽癌的初步观察．广西医学，1999，21(3)：37 3-375．
[65] 陶仲强，司勇锋，张政，等．鼻咽癌的局部免疫治疗．陕西肿瘤医学，2001，9(2)：93-94．
[66] 苏勇，张锦明，黄晓明，等．IL-2在鼻咽癌化疗、放疗中的免疫调节作用．实用癌症杂志，2000，15(5)：499-501．
[67] 梁平，苏贞栋，梁静英，等．放疗并局部注射IL-2治疗鼻咽癌颈淋巴结转移残存的临床评价．中国临床药理学和治疗学，2002，7(4)：347-348．
[68] 吴玮，周水淼，李兆基，等．肿瘤坏死因子抗人鼻咽癌细胞的活性．第二军医大学学报，1997，18(3)：266-268．
[69] 董伟达，周蓉珏，周水淼，等．新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究．中华耳鼻咽喉科杂志，1998，33(1)：38-41．
[70] Steinman RM, Cohn ZA. Identification of a novell cell type in peripheral lymphoid organs of mice. Ⅰ. Morphology, quantiaton, tissue distribution. J Exp Med, 1973;137:1142-1162.
[71] Girolomoni G, Ricciardi-Castagnoli. Dendritic cells hold promise for immunotherapy. Immunology Today, 1997, 18:102-104.
[72] Schuler G, Steinman M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med, 1997, 186: 1183-1187.
[73] Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001, 106: 259-262.
[74] 丁传林，姚堃．树突状细胞的发育、亚群及其对T细胞应答类型的调控．上海免疫学杂志，2002，22：347-349．
[75] 朱学军，曹雪涛，马施华，等．人骨髓、脐血CD34~+干细胞体外扩增的树突状细胞的表型及其T细胞刺激活性分析．中国肿瘤生物治疗杂志，1999，6：22-26．
[76] 王晓，裴雪涛，李梁，等．脐血CD34~+细胞和外周血单核细胞两种来源的树突状细胞的特性的比较研究．中华血液杂志，1999，20：583-585．
[77] 谢芳艺，姚垫，王胜军，等．人外周血单核细胞体外诱导树突状细胞及鉴定．南京医科大学学报，2001，21：111-114．
[78] 王月丹，谢玮，邱玉华，等．细胞因子诱导不同来源的贴壁细胞分化为树突状细胞的研究．上海免疫学杂志，2000，3：140-144．
[79] 钱一峰，厉永建．树突状细胞与T辅助细胞分化．国外医学免疫学分册，2001．24：147-150．
[80] Tarte K, Klein B. Dendritic cell-based-vaccine: a promising approach for cancer immunotherapy. Leukemia, 1999, 13 (5): 653-663.
[81] Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev, 1999, 13 (1) :51-64.
[82] Subbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicitis protective cell-meiated immunity. Nat Med, 2001, 7 (5): 625-629.
[83] Marten A, Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother, 2000, 23 (4): 464-472.
[84] Celluzzi CM, Mayordommo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 1996,183 (1):283-287.
[85] Robbins PF, EI-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med, 1996,183 (3): 1185-1192.
[86] Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines J Exp Med, 1996, 183(1): 87-97.
[87] Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med, 1998, 4 (3): 328-332.
[88] Murphy G; Tjoa B, Ragde H, et al. Phase Ⅰ clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, 29 (6):371-380.
[89] Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. [J]. Cancer Res, 2001, 61 (17): 6445-6450.
[90]Dematos P, Abdel-wahab Z, Vervaert C, et al. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol, 1998, 185 (1): 65-74.
[91] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med, 1997,186 (7):1177-1182.
[92] Wan Y, Bramson J, Carter R, et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther, 1997,8(11): 1355-1363.
[93]Rea D, Johnson ME, Havenga MJE, et al. Strategies for improved antigen delivery into dendritic cells. TRENDS in molecular Medicine, 2001, 7: 94.
[94] Jenne L, Schuler G, Steinkasserer A, etal. Viral vectors for dendritic cell-based immunotherapy. TRENDS in immunology, 2001, 22: 102-107.
[95] Zhong L, Piperno AG, C hoi Y, etal. Recomibinant adenovirus is an efficient and non-perturbing genetic vector for human dendertic cells. Eur J Immunol, 1999, 29: 964-972.
[96]Dietz AB and Vuk-parlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood, 1998, 91: 392-398.
[97] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly (L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[98]Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods, 2000, 241: 69-81.
[99]Drillien R, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000, 268: 471-481.
[100] Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA, 1997,94 (7): 3183-3188.
[101] Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T response. J Exp Med, 1997,185: 1605-1617.
[102]Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol, 1999, 162: 3063-3069.
[103]Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol, 1997,15: 405-431.
[104]Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[105] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNAI [J]. J Immunol, 2000, 165:7078.
[106] Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res, 2002, 62 (1): 171-178.
[107] 姚堃，谢芳艺，许继军，等．EB病毒潜伏期膜蛋白2A基因重组痘苗病毒转染DC及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[108] Steven PL, Rosemary JT, Wendy AT, et al. Lee SP, Tierney RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[109] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[110] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus-specific T cell memory with peptide loaded dendritic cells. J of Virol, 1999, 73: 334-342.
[111] Subklewe M, Chahroudi A, Schmaijohn A, et al. Induction of Epstein-Barr virus specific cytotoxic T lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or uv-inactivated recombinant EBNA-3A vaccinia virus. Blood, 1999, 94: 1372-1381.
[112] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[113] Su Z, Peluso MV, Raffegerst SH, et al. The generation of Lmp2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr viruspositive Hodgkin disease. Eur J Immunol, 2001,31: 947-958.
[114] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to Lmp2A antigen: a potential treatment strategy for Epsstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[115] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B:a new modality for vaccination. J Virol, 1999, 7: 10416-10425.
[1] Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in Nasopharyngeal Carcinoma(NPC): Evidence for efficient presentation of Epstein-Ban" virus cytotoxic T-cell epitopes by NPC cells. Cancer Res, 1998, 58: 310-314.
[2] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451-1456.
[3] Steven PL, Rosemary JT, Wendy AT, et al. Lee SP, Tiemey RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[4] 洪明晃，郭翔主编．鼻咽癌．第1版．北京：中国医药科技出版社，2003，12．
[5] 冯浩森 综述，黄宗海审校．肿瘤疫苗的研究现状与进展．中国肿瘤临床与康复，2000，8(6)：124-126．
[6] 常卫红 综述．肿瘤疫苗研究进展．中国实用外科杂志，2001，21(9)：566-568．
[7] Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds.Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[8] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNA1 [J]. J Immunol, 2000, 165:70-78.
[9] Nonkwelo C, Skinner J, BellA, et al.Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.J virol, 1996, 70: 623-627.
[10] Wilson JB, Bell JL. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic. EMBO J, 1996, 15: 3117-3126.
[11] Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 1995, 375: 685-688.
[12] Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigenl. Proc Natl Acad Sci USA, 1997, 94: 12616-12621.
[13] Khanna R, Burrows SR, Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54:19-48.
[14] Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T lymphocyte control of EBVassociated malignancies. J Virol, 1996, 70: 5357-5362.
[15] Murry RJ, Young LS, Calender A, et al. Different patterns Epstein-Barr virus gene expression and cytotoxic T cell recognition in B cell lines infected with transforming (B95.8) or nontransforming (P3hR2) virus strains. J Virol, 1988, 62(3) :894-901.
[16] Murray RJ, Brooks JM, Rickinson AB, et al. Cross- recognition of a mouse H-1 peptide complex by human HLA-restricted cytotoxic T cells. Eur J Immunol, 1990, 20 (3): 659-664.
[17] 杨成勇，蔡伟民，沈倍奋，等．鼻咽癌患者EB病毒潜伏膜蛋白(LMPlA)的特异性细胞免疫研究．病毒学报，1999，15(3)：193-198．
[18] 周玲，姚家伟，陈志坚，等．免疫斑点法检测特异性EBV潜伏膜蛋白2合成肽的细胞毒T淋巴细胞．中华实验和临床病毒学杂志，2000，14(4)：384-385．
[19] Dawson CW, Rickinson AB, Young LS, et al. Epstein-Barr virus latent membrane protein inhibts human epithelial cell differentiation. Nature, 1990, 344 (6268): 777-781.
[20] Fahraeus R, Rymo L, Rhim JS, et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature, 1990, 345 (6274): 447-449.
[21] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[22] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol: Mol Pathol, 2000, 53 (5): 248-254.
[23] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly (L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[24] Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulat.ory capacity. J Immunol Methods, 2000, 241:69-81.
[25] Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000, 268:471-481.
[26] Murray RJ, Kurilla MG; Brooks JM, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med, 1992, 176: 157-168.
[27] Lettenne ET, Winberg G, Yadav M, et al. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur I Cancer, 1995,31: 1875-1878.
[28] Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1 [J]. J Ep Metl, 2000, 191: 1649-1660.
[29] Bickham K, Munz C, Tsang ML, et al. EBNAl-specific CD_4~+T cells in healthy carriers of Epstein-Barr virus are primarily Thl in function [J]. J Clin Invest, 2001, 107(1): 121-130.
[30]Babcock GJ, Decker LL, Freeman RB, et al. Epstein-barr virus infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients [J]. J Exp Med, 1999, 190 (4): 567-576.
[31] Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol, 1992,66 (5): 2689-2697.
[32] Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol, 1992, 66 (5): 3257-3262.
[33]Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[34]Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[35] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[36] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001,93:706-713.
[1] Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 1997, 90: 3245-3287.
[2]Inaba K. Dendritic cells as antigen-presenting cells in vivo. Immunol Cell Biol, 1997, 75: 206-208.
[3] Mailliard RB, Dallal RM, Son Yi, et al. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen [J]. Immunol Invest, 2000,29 (2): 177-185.
[4] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 1991, 9: 271-296.
[5]Dubois B, Vanbervliet B, Fayette J, et al. Dendritic cells enhance growth and differentiation of CD40- activated B lymphocytes. J Exp Med, 1997, 185: 941-951.
[6]Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 1998, 392: 245-252.
[7] Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med, 1999,50:507-529.
[8] Hsu FJ, et al. Vaccination of patients with B-cell lmphoma using autologous antigen-pulsed dendrtic cells. Nat Med, 1996,2: 52-59.
[9]Strunk D, Egger C, Leitner G, et al. A skin homing molecule defines the Langerhans cell progenitor in human peripheral blood. J Exp Med, 1997, 185: 1131-1136.
[10]Karolina AP, Nicolas T, Francoise SC, et al. Dendritic cells as the terminal stage of monocytes differentiation. J Immunol, 1998,160: 4587-4595.
[11] Res P, Martinez CE, Cristina JA, et al. CD34~+CD38~(dim) cells in the human thymus can differentiate into T, Nature Killer, and dendritic cells but are distinct from pluripotent stem cells. Blood, 1996, 87: 5196-5206.
[12] Steinman RM, Cohn ZA. Identification of a novell cell type in peripheral lymphoid organs of mice.I. Morphology, quantiaton, tissue distribution. J Exp Med, 1973,137:1142-1162.
[13] Young JW, Szabolcs P, Moore MAS. Identification of dendritic cell colony-forming units among normal human CD34~+ Bone marrow progenitors of GM-CSF and TNF-a. J Exp Med, 1995, 182: 1111-1120.
[14]Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA, 1997, 94: 12551-12556.
[15] Burt RK, Link C, Traynor A. Adoptive immunotherapy after hematopoietic stem cell transplantation. Curr Opin Onco, 1998,10: 525- 532.
[16] Van Voorhis WC, Hair LS. Steinman RM, et al. Human dentritic cells. Enrichment and characteristation from peripheral blood. J Exp Med, 1982, 155: 1172-1187.
[17] Dallal RM, Lotze MT. The dendritic cells and human cancer vaccines. Current Opinion in immunology, 2000,12: 583-588.
[18] Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol, 2000, 18: 245-273.
[19] Romani N, Gnmer S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med, 1994, 180: 83-93.
[20] 王月丹，谢玮，邱玉华等．细胞因子诱导不同来源的贴壁细胞分化为树突状细胞的研究．上海免疫学杂志，2000，3：140-144．
[21] 朱学军，曹雪涛，于益芝等．人外周血树突状细胞的体外扩增及鉴定．中国肿瘤生物治疗杂志，1997，4：302-306．
[22] 王晓，裴雪涛，李梁，等．脐血CD34~+细胞和外周血单核细胞两种来源的树突状细胞的特性的比较研究．中华血液杂志，1999，20：583-585．
[23] 谢芳艺，姚堃，王胜军，等．人外周血单核细胞体外诱导树突状细胞及鉴定．南京医科大学学报，2001，21：111-114．
[24] Chapuis F, Rosenzwajg M, Yagello M, et al. Differentiation of human dentritic cells from monocytes in vitro. Eur J Immunol, 1997, 27: 431-441.
[25] Alters SE, Gadea JR, Holm B, et al. IL-13 can substitute for IL-4 in the generation of dentritic cells for the induction of cytotoxic T lymphocytes and gene therapy. J Immunother, 1999, 22: 229-236.
[26] Ferlazzo G, Klein J, Paliard X, et al. Dentritic cells generated from CD_34~+ Progenitor cells with fit3 ligand, c-kit ligand, GM-CSF, IL-4, TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dentritic cells. J Immunother, 2000, 23: 48-58.
[27] Rosenzwajg M, Camus S, Guigon M, et al. The influence of interleukin (IL)-4,IL-13 and Flt3 ligand on human dendritic cell differentiation from cord blood CD34~+ progenitor cells. Exp Hematol, 1998, 26: 63-72.
[28] Alzona MT, Smith SL, van Epps DE, et al. Blood, 1996, 88 (suppl 1): 109a.
[29] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 1994, 179: 1109-1118.
[30] Engering AJ, Cella M, Fluitsma DM, et al. Mannose receptor mediated antigen uptake and presentation in human Dentritic cells. Adv Exp Med Biol, 1997, 417:183-187.
[31] Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 1997, 15: 94-103.
[32] Nouri-Shirazi M, Banchereau J, Fay J, et al. Dendritic cell based tumor vaccines. Immunology Letters, 2000, 74: 5-10.
[33] Gunzer M, Janich S, Varga G, et al. Dendritic cells and tumor immunity. Seminars in Immunology, 2001, 13: 291-302.
[34] Rhea D, Johnson ME, Havenga MJE, et al. Strategies for improved antigen delivery into dendritic cells. TRENDS in molecular Medicine, 2001, 7: 91-94.
[35] 鲁严，张学光．不同形式的肿瘤抗原负载树突状细胞的比较．癌症，2000，19：724-726．
[36] Jenne L, Schuler G, Steinkasserer A, et al. Viral vectors for dendritic cell-based immunotherapy. TRENDS in immunology, 2001, 22: 102-107.
[37]Zhong L, Piperno AG, Choi Y, et al. Recombination adenovirus is an efficient and non-perturbing genetic vector for human demdritic cells. Eur J Immunol, 1999, 29: 964-972.
[38] Mulders P, Pang S, Daannull J, et al. High efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjutages. Cancer Research, 1998, 58: 956-961.
[39]Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 2000,268(2): 471-481.
[40]Szabolcs P, Gallardo HF, Ciocon D H, et al. Retrovirally transduced human dendritic cells expressed a normal phenotype and potent T cell stimulatory capacity. Blood, 1997, 90: 2160-2167.
[41]Rouard H, Leno A, Klonjkowski B, et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances constimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods, 2000, 241: 69-81.
[42]Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J.Virol, 1999, 73: 334-342.
[43] Subklewe M, Paludan C, Tsang ML, et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand Tumor-reactive CD8~+ killer T cells. J Exp Med, 2001, 193: 405-411.
[44] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[45] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001,93: 706-713.
[46]Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol, 2000, 53: 248-254.
[1] Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science, 1997, 276: 1684-1687.
[2] Stenger S, Modlin RL. Cytotoxic T cell responses to intracellular pathogens. Curr Opin Immunol, 1998, 10: 471-477.
[3] Baumforth KRN, Young LS, Flavell KJ, et al. Demystified...The Epstein-Barr virus and its association with human cancers. J Clin Pathol: Mol pathol, 2000, 52 (6): 307-322.
[4] Khanna, R, Burrows SR, Moss DJ, et al. Immune regulation in Epstein-Barr virus associated diseases. Microbiol Rev, 1995, 59: 387-405.
[5] 王冬，贾心善．EB病毒相关肿瘤研究的新进展．国外医学，生理、病理科学与临床分册，1999，19(5)：338-405．
[6] Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies:a review. J Clin Pathol, 2000, 53: 248-254.
[7] Straahof KC, Bollard CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children [J]. Oncologist, 2003, 8 (1): 83-98.
[8] Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection[J]. Blood, 2002, 100 (12) :4059-4066.
[9] Rooney CM, Aguilar LK, Huls MH, et al. Adoptive immunotherapy of EBVassociated malignancies with EBV-specific cytotoxic T-cell lines [J]. Curr Top Microbiol Immunol, 2001, 258:221-229.
[10] 骆建民，李恩民，李德锐，等．EB病毒和鼻咽癌．汕头大学医学院学报， 2000，13(3)：67-70．
[11] 黎明，曹亚．EB病毒编码的蛋白质在癌变过程中的作用．国外医学，微生物学分册，2001，24：14-16．
[12] Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol : Mol Pathol, 2000, 53 (5): 248-254.
[13] Everett EV, David NL, Ralph W. Nasopharyngeal carcinoma. The Lancet, 1997, 350: 1087-1091.
[14] Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer, 2002, 94 (3):723-729.
[15] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[16] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451-1456.
[17] 姚堃，谢芳艺，许继军，等．EB病毒潜伏期膜蛋白2A基因重组痘苗病毒转染DC及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[18] Lee SP, Tiemey RJ, Thomas WA, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[19] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[20] Rickinson A, E Kieff. Epstein-Barr virus[A]. Fields Virology [M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[21] Fong L, Engleman EG. Dendritic cells in cancer immunotherapy [J]. Annu Rev Immunol, 2000, 18: 245-273.
[22] Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Annu Rev Microbiol, 2000, 54:19-48.
[23] Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAPol and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T-lymphocyte control of EBVassociated malignancies. J Virol, 1996, 70: 5357-5362.
[24] Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol: Mol Pathol, 2000, 53 (5): 238-247.
[25] Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res, 2002, 62 (1): 171-178.
[26] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[27] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[28] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 1999, 7: 10416-10425.
[29] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001.93: 706-713.
[30] 杜海军，周玲，左建民等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究[J]．肿瘤学杂志，2004，10(2)：92-94．
[31] Su Z, Peluso MV, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol, 2001, 31: 947-958.
[32] Savoldo,B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus native individuals. J Immnol, 2002, 168:909-918.
[33] Subklewe M, Paludan C, Tsang ML, et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand Tumor-reactive CD8+ killer T cells. J Exp Med, 2001, 193:405-411.
[34] Leen A, P Meij, Ⅰ Redchenko, et al. Differential immunogenicity of Epstein-Ban virus (EBV) latent cycle proteins for human CD_4~+ T helper 1 responses [J]. J Virol, 2001, 75 (18): 8649-8659.
[35] Zhong L, Pipemo AG, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol, 1999, 29: 964-972.
[1] Cheng SW, Ting AC, Lam LK, et al. Carotid Stenosis After Radiotherapy for Nasopharyngeal Carcinoma. Arch Otolaryngol Head Neck Surg, 2000, 126: 517-521.
[2] Lam HC, Abdullah VJ,, Wormald PJ, et al. Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base. Otolaryngology-Head and Neck Surgery, 2001, 125(5): 522-527.
[3] 中国抗癌协会。新编常见恶性肿瘤诊治规范-鼻咽癌分册[M]．北京：北京医科大学中国协和医科大学联合出版社，1999．
[4] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334-342.
[5] Marten A, Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother, 2000, 23 (4):464-472.
[6] Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med, 1996, 183: 87-97.
[7] Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med, 1998, 4 (3): 328-332.
[8] Murphy G, Tjoa B, Ragde H, et al. Phase Ⅰ clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, 29 (6): 371-380.
[9] Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines [J]. Cancer Res, 2001, 61 (17): 6445-6450.
[10] Demators P, Abdel-wahab Z, Vervaert C, et al. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. Cell Immunol, 1998, 185: 65-74.
[11] Zhang Haiging, Yao Kaitai, Zhu Hecheng, et al. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma epithelial cell line. Int J Cancer, 1990, 46: 944-949.
[12] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[13] Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med, 1992, 176: 157-168.
[14] Su Z, Peluso M, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol, 2001, 31: 947-958.
[15] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[16] Bollard CM, Straathof KCM, Helen Huls M, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother, 2004, 27(4): 317-327.
[17] 姚堃，谢芳艺，许继军，等．EB病毒潜伏膜蛋白2A基因重组痘苗病毒转染Dc及特异性CTL的体外诱导．细胞与分子免疫学杂志，2001，17：402．
[18] 杜海军，周玲，左建民等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究[J]．肿瘤学杂志，2004，10(2)：92-94．
[19] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumorextracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med, 1997, 186:1177-1182.
[20] liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg, 1999, 90: 1115-1124.
[21] 雷晓，余佩武，石彦，等．树突状细胞肿瘤疫苗诱导抗胃癌作用的实验研究．中华胃肠外科杂志，2002，5(1)：45-48．
[22] 刘福生，王忠诚，历俊华，等．肿瘤抗原致敏树突状细胞瘤苗治疗颅内胶质瘤的实验研究．中华神经外科杂志，2002，18(2)：91-95．
[1] Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients [J]. Proc Natl Acad sci USA, 1987, 84(9):2911-2915.
[2] Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine,1998,4(3):321-327
[3]Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol, 1996,157: 2539-2548.
[4] Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response [J]. J Immunother,1999,22 (4): 288-298.
[5]Zaremba S, Brazaga E, Zhu MZ, et al. Identification of an enhancer agonist cytotoxic T ymphocyte peptide from human carcinoembryonic antigen Cancer Res, 1997, 57: 4570-4577.
[6] Esserman LJ, Lopez T, Montes R, et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice [J]. Cancer Immunol Immunother, 1999,47 (6):337-342.
[7]Ohnishi Y, Fujii H,Murakani K, et al. A new pseudo-peptide analogue of the Arg-Gly-Asp (RGD) sequence inhibits liver metastasis of colon 26-L5 carcinoma cells. [J]. Cancer Letters, 1998,124: 157-163.
[8] Bonfanti M, Tavema S, Salmona m, et al. p21 WAF1 -derived peptides linked to an internalization peptide inhibit human cancer cell growth. [J]. Cancer Research, 1997, 57: 1442-1446.
[9] Tuteja R. DNA vaccines: a ray of hope [J]. Crit Rev Biochem Mol Biol, 1999, 34 (1): 1-24.
[10] Han R, et al. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Viral, 2000, 74 (20): 9712-9716.
[11] Bohm W, et al. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection Cancer Immunol Immunother,1997,44(4):230-238.
[12] White SA, et al. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine J Gene Med,2000,2(2):135-140.
[13]Xiang R,Silletti S, Lode HN, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice [J].Clin Cancer Res, 2001,7 (3 Suppl): 856s-864s.
[14] Geissler M, Wands G, Gesien A, et al. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. [J]. Lab Invest, 1997,76 (6): 859-871.
[15] Park JH, et al. Effective immunotherapy of cancer by DNA vaccination. Mol Cells,1999,9(4): 384-391.
[16] Nawrath M, Pavlovic J, Dummet R, et al. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17.[J]. Leukemia, 1999,13 (Suppl 1): S48-51.
[17]Petersen TR, et al. Human p53 (264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett, 1999,137(2): 183-191.
[18] Chen Y , Hu D, Eling DJ, et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.[J]. Cancer Res,1998, 58 (9): 1965-1971.
[19]Amici A, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice Gene Ther, 2000,7 (8): 703-706.
[20]Rakhmilevich AL, Janssen K,Turner J, et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12.[J]. Hum Gene Ther, 1997, 8 (11): 1303-1311.
[21]Mendiratta SK, Thai G, Eslaki NR, et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. [J]. Cancer Res, 2001, 61 (3): 859-862.
[22]Yoshimura K, et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther, 2001, 8 (1): 9-16.
[23] Irvine KR, Rao JB, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases [J]. J Immunol, 1996, 156 (1): 238-245.
[24] Chamberlain RS. Prospects for the therapeutic use of anticancer vaccines.[J]. Drugs, 1999, 57(3): 309-325.
[25]Hui K,Grosveld F, Festenstein H, et al. Rejective of transplantable AKP leukaemia cells following MHC DNA-mediated cell transformation [J]. Nature , 1984, 311 (6010): 750
[26] James RF, Edwards S, Hui RM, et al. The effect of class 2 gene transfection on the tumorigenicity of the H-2k-negative mouse leukaemia cell line K36.16. [J]. Immunology, 1991, 72(2): 213-218.
[27] Schwann RN. Costimulation of T lymphocytes: the role of CD28,CTL-4 and B7/ BB1 in IL-2 production and immunotherapy [J]. Cell, 992,71 (7): 1065-1068.
[28]Fenton RT, Bate SE, Sonnevel T, et al. A phase I trial of B7-transfected or parental lethally irradiated allogenetic melanoma cell lines to induce cell- mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage Ⅳ melanoma[J]. Human Gene Therapy, 1995; 6 (1): 87
[29] Thomas MC, Greten TF, Pardoll DM, et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther, 1998, 9 (6): 835-843.
[30]Manome Y, Wen PY, Hershowitz A, et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother, 1995,41 (4): 227-235.
[31]Thara H, Sandgren EP, Quaife CJ, et al. Antitumor effects of IL-12: application for the immunotherapy and gene therapy of cancer [J]. Ther Gene, 1995, 2 (2): 96
[32] Miller AR, Reters WT, Posner M, et al. Cytokine mediated gene therapy for cancer [J]. Am Surg Oncol, 1994, 1 (5): 436
[33]Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry [J]. J Clin Oncol, 1998,16: 2548-2556.
[34]Cebon JS, Cieschke GJ. Granulocyte-macrophage colony-stimulating factor for cancer treatment [J]. Oncology, 1994, 51(2): 177-188.
[35] Garcia VE, Jullien D,Song M, et al. IL-15 enhaunces the response of human gamma delta T cells to nonpeptide microbial antigens [J]. J Immunol, 1998, (Correctiom of non petide) 160 (9): 4322-4329.
[36] Osaki T, Peron JM, Cai Q, et al. INF-gamma-induced factor/IL-18 administration mediates INF-gamma and IL-12-independent antitumor effects[J]. Jimmunol, 1998,160(4): 1742-1749.
[37] Mullen CA, Petropoulos D, Lowe RM, et al. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res, 1996, 56(6): 1361-1366.
[38] Witting B, Marten A, Dorbic T, et al. Therapeutic vaccination anginst metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I /II trial. Hum Gene Ther, 2001,12 (3): 267
[39] Antonia SJ, Seigne JD. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol, 2000,18 (2): 157
[40]Tarte K, Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia, 1999,13 (5): 653
[41]Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev, 1999,13 (1): 51
[42]Subbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicitis protective cell-meiated immunity. Nat Med, 2001,7(5): 625
[43] Marten A,Schottker B, Ziske C, et al. Induction of the immunostimulatory effect of dendiitic cells by pulsing with CA 19-9 protein [J]. J Immunother , 2000, 23 (4): 464-472.
[44] Celluzzi CM, Mayordommo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 1996,18 (1) : 283-287.
[45]Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med, 1996,183(3): 1185-1192.
[46]Zitvogel L, Mayordomo, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 1996; 183 (1): 87-97.
[47] Nestle FO, Alijagic S, Gilliet M,et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998,4 (3): 328-332.
[48] Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996,29 (6): 371-380.
[49]Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines [J]. Cancer Res, 2001, 61(17): 6445-6450.
[50]Dematos P, Abdel-wahab Z, Vervaert C, et al. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol, 1998, 185 (1): 65-74.
[51] Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med,1997,186 (7): 1177-1182.
[52] Wan Y, Bramson J, Carter R, et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.. Hum Gene Ther, 1997, 8 (11): 1355-1363.
[53] Gong J, Avigan D, Chen D, et al. activation of antitumor cytotoxic T lymphocytes by fushions human dendritic cells and breast carcinoma cells. [J]. Proc Natl Acad Sci USA, 2000, 97 (6): 2715-2718.
[54] Gong J, Nikrui N, Chen D, et al. Fushions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. [J]. J Immunol, 2000, 165 (3): 1705-1711.
[55]Kugler A, Stuhler G, Walden P. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med, 2000, 6 (3): 332
[56] Hsu FJ,Benike C,Fagnoni F,et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 1996,2 (1): 52-58.
[57] Okada N, Tsujino M, Hagiwara Y, et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.[J]. Br J Cancer, 2001, 84(11): 1564-1570.
[58] Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.[J]. Cancer Res, 2001, 61 (2): 641-646.
[59] Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA, 1997,94 (7): 3183-3188.
[60] Mulders P, Pang S, Dannull J, et al. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates Cancer Res ,1998;58(5):956-961.
[61]Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage iVmelanoma[J]. Proc Natl Acad sci USA, 1992, 89 (2): 466-470.
[62] Durrant LG, Maxwell-Armstrong C, Buckley D, et al. A neoadjuvant clinical trial in colorental cancer patients of the human anti-idiotypic antibody 105 AD7, which mimics CD55. Clin Cancer Res, 2000,6 (2): 422
[63] Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. [J]. J Clin Oncol, 1999, 17(9): 2889-2895.
[64] Hamilton JM, Chen AP, Nguyen B, et al. Phase I study of recombinant vaccinia virus that expresses human carcinoembryonic antigen in adult patients with adenocarcinoma [J]. Proc Am Soc Clin Oncol, 1994, 13:295
[65] Schlag P, Manasterski M, Gerneth Thomas, et al. Active specific immuno-therapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evalution of clinical response of a phase Ⅱ trial[J]. Cancer Immunother, 1992, 35 (5):325-330.
[66] Gou YJ, Wu MC, Chen H, et al. Effective tumor vaccine generated by fusion of hepatoma cells with actived B cells[J]. Sci, 1994, 263:518-520.
[67] 冯浩森 综述，黄宗海审校．肿瘤疫苗的研究现状与进展．中国肿瘤临床与康复，2000，8(6)：124
[67] 常卫红 综述．肿瘤疫苗研究进展．中国实用外科杂志，2001，21(9)：566
[68] 刘衫杉 综述．叶胜龙审校．国外医学肿瘤学分册，1999，26(3)：131
[69] 王鹏飞 综述．肿瘤疫苗的研究进展．国外医学免疫学分册，2002，25(4)：220
[70] 温斌 综述．DNA疫苗与抗肿瘤免疫．国外医学免疫学分册，2003，26(1)：17
[1] Mesic JB, Fletcher GH, Geopfert H, et al. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys, 1981, 7: 447-453.
[2] Cheng SW, Ting AC, Lam LK, et al. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg, 2000; 126 (4) :517-521.
[3] Lam HC, Abdullah VJ, Wormald PJ, et al. Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base. Otolaryngology - Head and Neck Surgery, 2001;125 (5) : 522-527.
[4] Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 1993, 120 (1-2): 115-118.
[5] Townsend SE, Allison JP. Tumor rejection after direct costimulation of CDS+ T cells by B7-transfected melanoma cells, Science, 1993; 259(5093): 368-370
[6] 杨世成，李树浓，刘芳等．转染B7-1基因至鼻咽癌细胞株及其诱导的细胞免疫应答．免疫学杂志，1998；14(3)：172-175
[7] Nisonoff A, Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin Immunopathol, 1981; 21 (3): 397-406
[8] Li GC, Xie L, Zhou GH, et al. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients. Chinese Medical Journal, 2002; 115(4): 567-570
[9] 谢鹭，李官成，孙去病，等．用抗独特型抗体主动免疫增强鼻咽癌放疗病人的免疫功能．中国肿瘤临床，1998；25(3)：168-171
[10] Rickinson A, Kieff E. Epstein-Barr virus[A]. Fields Virology[M]. DM Knipe, PM Howley, eds. Philadelphia, New York: Lippincott Williams & Wilkins, 2001.2575.
[11] Blake NT, Haigh, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD_8~+ T cell response: lessons from the EBV nuclear antigen EBNA1 [J]. J Immunol, 2000, 165:7078.
[12] Subklewe M, Chahroudi A, Schmaijohn A, et al. Induction of Epstein-Barr virus specific cytotoxic T lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or uv-inactivated recombinant EBNA-3A vaccinia virus. Blood, 1999, 94: 1372-1381.
[13] Rooney CM, Roskyow MA, Suzuki N. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol, 1998, 9 (Suppl 5): S129-132.
[14] Su Z, Peluso MV, Raffegerst SH, et al. The generation of Lmp2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol, 2001,31: 947-958.
[15] Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to Lmp2A antigen: a potential treatment strategy for Epsstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer, 2001, 93: 706-713.
[16] Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B:a new modality for vaccination. J Virol, 1999, 7:10416-10425.
[17] Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82:1451-1456.
[18] Steven PL, Rosemary JT, Wendy AT, et al. Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
[19] 朱伟严，周玲，王琦，等．EB病毒潜伏期膜蛋白2 DNA疫苗的构建及其初步免疫效果观察．中华微生物和免疫学杂志，2002，22：185-190．
[20] 徐洁洁，姚堃，俞晨杰，等．EB病毒LMP2A在鼻咽癌患者肿瘤组织中的表达及意义．临床耳鼻咽喉科杂志，2005，19(11)：484-487．
[21] 杜海军，周玲，左建民，等．EBV-LMP2多肽所激活的特异性CTL对鼻咽癌细胞杀伤活性的研究．肿瘤学杂志，2004，10(2)：92-94．
[22] 徐洁洁，姚堃，俞晨杰，等．EB病毒潜伏膜蛋白2A诱导细胞毒性T细胞抗鼻咽癌的体内外实验．中华耳鼻咽喉头颈外科杂志，2006，41(1)：54-59．
[23] 曾春林，孙安涛，杜娟，等．白细胞介素-Ⅱ和L A K细胞对放疗后鼻咽癌患者细胞免疫功能的影响，2000；17(2)：88-89．
[24] 梁振强，陆海杰，黎福祥，等．CD3 AK细胞配合放疗治疗鼻咽癌的初步观察．广西医学．1999；21(3)：37 3-375．
[25] Redchenko Ⅳ, Rickinson AB. Accessing Epstein-Barr virus-specific T cell memory with peptide loaded dendritic cells. J of Virol, 1999, 73: 334-342.
[26] 崔运昌，汪美先，王伯潭，等．人鼻咽癌上皮样细胞系的单克隆抗体(简报)．第四军医大学学报，1984，5：209-211．
[27] 孙去病，郭敏，李小玲，等．鼻咽癌的单克隆抗体研究：杂交瘤细胞系的建立及初步鉴定．湖南医学院学报，1987，12(1)：1-3．
[28] 李官成，朱建高，周国华，等．体内体外联合免疫法制备抗鼻咽癌单克隆抗体．湖南医学，1999；16(5)：326-328．
[29] Green WC, Leonard WJ, Deppen TM, et al. The human inter-leukin 2 receptor: normal and abnormal express in T cell and in leukemia induced by the human T-lymphotropism retroviruses[J]. Ann Inem Med, 1986,105:560-572.
[30] 陶仲强，司勇锋，张政，等．鼻咽癌的局部免疫治疗．陕西肿瘤医学，2001，9(2)：93-94．
[31] 苏勇，张锦明，黄晓明，等．IL-2在鼻咽癌化疗、放疗中的免疫调节作用．实用癌症杂志，2000，15(5)：499-501．
[32] 梁平，苏贞栋，梁静英，等．放疗并局部注射IL-2治疗鼻咽癌颈淋巴结转移残存的临床评价．中国临床药理学和治疗学，2002，7(4)：347-348．
[33] 吴玮，周水淼，李兆基，等．肿瘤坏死因子抗人鼻咽癌细胞的活性．第二军医大学学报，1997，18(3)：266-268．
[34] 董伟达，周蓉珏，周水淼，等．新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究．中华耳鼻咽喉科杂志，1998，33(1)：38-41．
[35] 张康，吴伟健．鼻咽癌患者放疗前外周T细胞及其亚群的检测与临床分期的关系．癌症，1995：14(5)：380-381．
[36] 张学荣，舒雨雁，王绍丰，等．胎盘免疫调节因子对鼻咽癌放疗病人免疫功能的影响．广西医科大学学报，1997；14(1)：25-27．
[37] 胡永红，夏云飞，罗伟，等．血卟啉衍生物配合放疗对鼻咽癌患者免疫功能的影响及3年疗效观察．中国肿瘤临床，2000；27(6)：466-467．
[38] 邱健行，陈宁，冯惠强，等．薏苡仁酯配合化学药物治疗晚期鼻咽癌的临床研究．华夏医学，2002；15(1)：5-7．
[39] 李坚，陆永奎．参麦注射液对鼻咽癌放疗病人免疫功能的影响．中国中医急症，1998；7(3)：118-119．
[40] 谢方云，曾智帆，黄惠英，等．放疗联合人参多糖注射液治疗鼻咽癌的临床观察．中国中西医结合杂志，2001；21(5．)：332-334．
[41] 穆美云，田洁，郜岚，等。黄芪对EB病毒核壳抗原IgA抗体阳性的作用。中华耳鼻咽喉科杂志，1993，28(1)：38-40．
[42] Csatary L, Gergely P. Vaccine therapy of malignant tumors[J]. Orv Hetil, 1990, 131 (47): 2585-2588.
[43] 李杰恩，徐志丈，毛荣清，等．新城疫病毒疫苗对晚期鼻咽癌患者细胞免疫功能的影响．细胞与分子免疫学杂志，2001，17(2)：155-156．
[44] 刘名光，邝国乾，张奕敬，等．新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察．癌症，2000；19(10)：912-915．
[44] 邝国乾，谢成熹，黄光武，等．新城疫病毒疫苗对自然人群EB病毒VCA-IgA抗体转阴作用初步报告．广西医科大学学报，1998，15(4)：4-6．
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |